详情页 - 云南省第一人民医院机构库

当前位置：首页 > 详情页

Clinical Evaluation of a Metagenomics-Based Assay for Pneumonia Management.

40| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]State Key Laboratory of Respiratory Disease, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, Guangzhou, China, [2]Vision Medicals Co., Ltd., Guangzhou, China, [3]Key Laboratory of Animal Gene Editing and Animal Cloning in Yunnan Province and College of Veterinary Medicine, Yunnan Agricultural University, Kunming, China, [4]Department of Thoracic Surgery, Guangzhou Institute for Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, [5]Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Southern University of Science and Technology, Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen Institute of Respiratory Diseases, Shenzhen, China

出处：

DOI：

ISSN：

关键词： pneumonia metagenomic next-generation sequence pathogens cytomegalovirus pneumocystis jirovecii

摘要：

Clinical value of metagenomic next-generation sequencing (mNGS) in pneumonia management is still controversial. A prospective study was conducted to evaluate the clinical impact of PneumoSeq in 57 immunocompetent (ICO) and 75 immunocompromised (ICH) pneumonia patients. The value of PneumoSeq for both etiological and clinical impact investigation in pneumonia was assessed. Among the 276 potential pathogens detected with PneumoSeq in our cohort, 251 (90.9%) were cross-validated. Clinical diagnoses of the causative pathogens were obtained for 97 patients, 90.7% of which were supported by PneumoSeq. Compared to conventional testing, PneumoSeq suggested potentially missed diagnoses in 16.7% of cases (22/132), involving 48 additional pathogenic microorganisms. In 58 (43.9%) cases, PneumoSeq data led to antimicrobial treatment de-escalation (n = 12 in ICO, n = 18 in ICH) and targeted treatment initiation (n = 7 in ICO, n = 21 in ICH). The PneumoSeq assay benefited the diagnosis and clinical management of both ICH and ICO pneumonia patients in real-world settings.Copyright © 2021 Zhan, Xu, He, Guan, Li, Li, Xie, Li, Chen, Cheng, Zhong and Ye.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区

生物

小类 | 2 区微生物学

最新[2023]版：

大类 | 2 区

生物学

小类 | 3 区微生物学

JCR分区：

出版当年[2020]版：

Q1 MICROBIOLOGY

最新[2023]版：

Q2 MICROBIOLOGY

影响因子： 4 最新[2023版] 5.1 最新五年平均 5.64 出版当年[2020版] 6.32 出版当年五年平均 4.236 出版前一年[2019版] 6.064 出版后一年[2021版]

第一作者：

第一作者机构： [1]State Key Laboratory of Respiratory Disease, Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, Guangzhou, China,

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

Clinical Evaluation of a Metagenomics-Based Assay for Pneumonia Management.

文献详情

相关文献